Antisense Therapeutics (Australia)

Recent papers from Antisense Therapeutics (Australia)

1. A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx micePLoS ONE · 2024
2. Inflammatory markers in persons with clinically-significant depression, anxiety or PTSD: A systematic review and meta-analysisJournal of Psychiatric Research · 2023
3. Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid proteinFrontiers in Immunology · 2023
4. A Phase 2 open-label study to determine the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy2022
5. T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID2021
6. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegalyEuropean Journal of Endocrinology · 2018
7. Effects of CD49d-targeted antisense-oligonucleotide on α4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studiesPLoS ONE · 2017
8. Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung diseaseRare Diseases · 2014
9. Transforming growth factor‐beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancerCancer Science · 2011
10. Configuration of the 5′-Methyl Group Modulates the Biophysical and Biological Properties of Locked Nucleic Acid (LNA) OligonucleotidesJournal of Medicinal Chemistry · 2010
11. Antisense oligonucleotide targeting of insulin‐like growth factor‐1 receptor (IGF‐1R) in prostate cancerThe Prostate · 2009
12. A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal miceJournal of Endocrinology · 2006
13. UV induced responses of the human epidermal IGF system: Impaired anti-apoptotic effects of IGF-I in HaCaT keratinocytesGrowth Factors · 2005
14. Interaction of Phosphorylated FcϵRIγ Immunoglobulin Receptor Tyrosine Activation Motif-based Peptides with Dual and Single SH2 Domains of p72Journal of Biological Chemistry · 1996